deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT02973321

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Sponsor: Sanofi

Conditions Type 2 Diabetes Mellitus
Interventions Liraglutide Metformin Placebo SAR425899
Updated 19 times since 2017 Last updated: Mar 15, 2022 Started: Dec 2, 2016 Primary completion: Dec 27, 2017 Completion: Dec 27, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Type 2 Diabetes Mellitus and is currently completed. Sanofi leads this study, which shows 19 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Nov 2017 · 3 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Mar 2021 — Apr 2022 [monthly]

    Completed PHASE2

▶ Show 14 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  2. Jan 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Dec 2018 — Jan 2019 [monthly]

    Completed PHASE2

  4. Jun 2018 — Dec 2018 [monthly]

    Completed PHASE2

  5. Jan 2018 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  8. Aug 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  9. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

  10. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE2

  11. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE2

  12. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Actopan, Mexico , Austin, United States , Balatonfüred, Hungary , Barcelona, Spain , Berlin, Germany , Budapest, Hungary , Chicago, United States , Dallas, United States , Denver, United States and 39 more locations